Hepatitis E Virus Infection in Pediatric Transplantation, a Prevalence Study
NCT ID: NCT02809885
Last Updated: 2017-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
226 participants
INTERVENTIONAL
2013-12-19
2017-12-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
HEV had a principally asymptomatic form. However, it was recently demonstrated that it could lead to a chronic form, especially in immunosuppressed patients. Moreover, in liver transplanted patients the infection could mimic a rejection and lead to the loss of the transplant. In other immunosuppressed patients, chronic hepatitis lead to cirrhosis and its well-known complications (ascitis, digestive hemorrhage, liver failure...). There is a lack of information about the prevalence of this disease.
In Canada the incidence of HEV infection was high (15-86% for liver transplanted children with liver tests disturbed). In Germany the prevalence was lower: 3,2% in liver \& kidney transplanted children whereas 7,4% in control. It was shown in a retrospective study that in liver (and liver+kidney) transplanted children the prevalence in Lyon was around 8,3%.
This study will determined in a prospective approach the HEV prevalence in kidney, lung, heart and bone marrow transplanted children in Lyon.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection
NCT01090232
HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver
NCT03488589
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
NCT01163240
Hepatitis E Virus Infection in Oncological Patients
NCT06631560
Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
NCT07038863
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transplanted patients
All patients included are in the same arm.
Hepatitis E serology
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hepatitis E serology
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* transplantation (heart, kidney, lung or bone marrow)
* protocol acceptance by family
* social security available
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospices Civils de Lyon
Bron, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Alain LACHAUX, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Noémie Laverdure, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-810
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.